


New, Advanced Panels for **Non-Small Cell Lung Cancer (NSCLC)**

Molecular testing in NSCLC:

Targeted therapy is increasingly turning standard of care for NSCLC patients and molecular testing is pivotal for its success. The presence of genetic alterations in the cancer cells which drive the growth of the tumor (Driver Alterations) allows the selection of treatment regime for individual NSCLC patients. Molecular tests identify the presence of oncogenic drivers and hence help indicate the apt targeted treatment regimen improving the probability of patient survival.



Markers Covered

EGFR, ALK, ROS1, BRAF, MET,
 PDL1, RET, Her2, MSI

NSCLC Panels

Mutations Covered

- SNVs (Single Nucleotide Variation) and InDels (Insertion-Deletion)
- Amplifications
- Skipping mutations

Testing Techniques

- NGS (Next-Generation Sequencing)
- IHC (Immunohistochemistry)
- Fragment Analysis

New Panels:

The new panels offers more insights into NSCLC of your patients. The panels cover various genes, cover various mutation types using multiple technologies.

Get in touch

MedGenome launches 5 new panels for NSCLC molecular testing with various combinations of markers covered and technology used. As follows:



Get in touch